BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 28668840)

  • 21. Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
    Yan W; Li R; He J; Du J; Hou J
    Cell Signal; 2015 Apr; 27(4):851-9. PubMed ID: 25643631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxisome proliferator-activated receptor α (PPARα) contributes to control of melanogenesis in B16 F10 melanoma cells.
    Grabacka M; Wieczorek J; Michalczyk-Wetula D; Malinowski M; Wolan N; Wojcik K; Plonka PM
    Arch Dermatol Res; 2017 Apr; 309(3):141-157. PubMed ID: 28084540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising preclinical activity of 2-methoxyestradiol in multiple myeloma.
    Dingli D; Timm M; Russell SJ; Witzig TE; Rajkumar SV
    Clin Cancer Res; 2002 Dec; 8(12):3948-54. PubMed ID: 12473611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study on the relationship of beta-catenin level and sensitivity to Bortezomib of myeloma cell lines].
    Zhou LL; Fu WJ; Yuan ZG; Wang DX; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):234-7. PubMed ID: 18843976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of PPAR alpha by fenofibrate inhibits apoptosis in vascular adventitial fibroblasts partly through SIRT1-mediated deacetylation of FoxO1.
    Wang WR; Liu EQ; Zhang JY; Li YX; Yang XF; He YH; Zhang W; Jing T; Lin R
    Exp Cell Res; 2015 Oct; 338(1):54-63. PubMed ID: 26226216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
    Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
    Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of Wnt signaling activity for growth suppression induced by quercetin in 4T1 murine mammary cancer cells.
    Kim H; Seo EM; Sharma AR; Ganbold B; Park J; Sharma G; Kang YH; Song DK; Lee SS; Nam JS
    Int J Oncol; 2013 Oct; 43(4):1319-25. PubMed ID: 23900432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
    Shan BE; Wang MX; Li RQ
    Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
    Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
    J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
    Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
    Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wogonin induces apoptosis in RPMI 8226, a human myeloma cell line, by downregulating phospho-Akt and overexpressing Bax.
    Zhang M; Liu LP; Chen Y; Tian XY; Qin J; Wang D; Li Z; Mo SL
    Life Sci; 2013 Jan; 92(1):55-62. PubMed ID: 23142241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
    Goel A; Dispenzieri A; Greipp PR; Witzig TE; Mesa RA; Russell SJ
    Exp Hematol; 2005 Jul; 33(7):784-95. PubMed ID: 15963854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
    Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
    Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of green tea polyphenol EGCG((-)-epigallocatechin-3-gallate) on the proliferation of gastric cancer cells by suppressing canonical wnt/β-catenin signalling pathway.
    Yang C; Du W; Yang D
    Int J Food Sci Nutr; 2016 Nov; 67(7):818-27. PubMed ID: 27338284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
    Zhou L; Hou J; Fu W; Wang D; Yuan Z; Jiang H
    Leuk Res; 2008 Nov; 32(11):1674-83. PubMed ID: 18485479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.
    Sukhdeo K; Mani M; Zhang Y; Dutta J; Yasui H; Rooney MD; Carrasco DE; Zheng M; He H; Tai YT; Mitsiades C; Anderson KC; Carrasco DR
    Proc Natl Acad Sci U S A; 2007 May; 104(18):7516-21. PubMed ID: 17452641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt/β-catenin/BCL-9 signaling pathway.
    Xu Y; Yang Z; Yuan H; Li Z; Li Y; Liu Q; Chen J
    Oncol Rep; 2015 Aug; 34(2):747-54. PubMed ID: 26081897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
    Kukreja A; Hutchinson A; Mazumder A; Vesole D; Angitapalli R; Jagannath S; O'connor OA; Dhodapkar MV
    Br J Haematol; 2007 Jan; 136(1):106-10. PubMed ID: 17222199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.